Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP19A1 | P11511 | 4/20 | 0.50 |
| ▸ | P2RX7 | Q99572 | 3/20 | 0.50 |
| ▸ | RECQL | P46063 | 1/20 | 0.46 |
| ▸ | GRM2 | Q14416 | 2/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.43 |
| ▸ | PKM | P14618 | 1/20 | 0.42 |
| ▸ | SLC9A1 | P19634 | 1/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 2/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | GALR3 | O60755 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | NPY1R | P25929 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3609829 | 0.81 | PKM (0.49) | CYP19A1GRM2ALDH1A1KDM4EPKM | |
| SCHEMBL3595251 | 0.81 | HTT (0.49) | CYP19A1ALDH1A1HPGDHSD17B10KDM4E | |
| SCHEMBL3612699 | 0.79 | GRM2 (0.52) | GRM2ALDH1A1HSD17B10KDM4ENPC1 | |
| SCHEMBL15824778 | 0.79 | HSD17B10 (0.48) | RECQLALDH1A1HSD17B10KDM4ERAB9A | |
| SCHEMBL4361625 | 0.78 | P2RX7 (0.56) | CYP19A1P2RX7RECQLGRM2ALDH1A1 | |
| SCHEMBL3605931 | 0.77 | KDM4E (0.44) | P2RX7GRM2ALDH1A1KDM4ENR1H2 | |
| SCHEMBL27807343 | 0.77 | NPBWR1 (0.51) | ALDH1A1ALOX15KDM4ESMN1; SMN2MAPT | |
| SCHEMBL4365345 | 0.76 | TSHR (0.56) | CYP19A1P2RX7RECQLALDH1A1TSHR | |
| SCHEMBL568868 | 0.76 | KDM4E (0.72) | CYP19A1P2RX7RECQLALDH1A1TSHR | |
| SCHEMBL15675375 | 0.76 | CYP19A1 (0.50) | CYP19A1P2RX7RECQLGRM2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 42 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-121758376-A | Preparation method of 1-substituted-1H-pyrazole-5-methyl formate-13C | 长沙贝塔医药科技有限公司 | 2026-03-31 | — | — | CN | disclosed |
| EP-4709725-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | Progentos Therapeutics, Inc. (US) | 2026-03-18 | — | — | EP | disclosed |
| US-12384777-B2 | Compounds comprising N-methyl-2-pyridone, and pharmaceutically acceptable salts | Tay Therapeutics Limited (GB) | 2025-08-12 | — | — | US | disclosed |
| CN-116134027-B | Heteroaryl-substituted 3- (1-oxo-isoindolin-2-yl) piperidine-2, 6-dione derivatives and uses thereof | 诺华股份有限公司 | 2025-01-24 | — | — | CN | disclosed |
| WO-2024233642-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | PROGENTOS THERAPEUTICS, INC. (US) | 2024-11-14 | — | — | WO | disclosed |
| CN-115819347-B | Preparation method of 1-alkyl-3-bromopyrazole | 暨明医药科技（苏州）有限公司 | 2024-08-30 | — | — | CN | disclosed |
| US-20230271940-A1 | HETEROARYL SUBSTITUTED 3-(1-OXOISOINDOLIN-2-YL)PIPERIDINE-2,6-DIONE DERIVATIVES AND USES THEREOF | NOVARTIS AG (CH) | 2023-08-31 | — | — | US | disclosed |
| US-20230271940-A1 | HETEROARYL SUBSTITUTED 3-(1-OXOISOINDOLIN-2-YL)PIPERIDINE-2,6-DIONE DERIVATIVES AND USES THEREOF | NOVARTIS AG (CH) | 2023-08-31 | — | — | US | disclosed |
| US-20230271940-A1 | HETEROARYL SUBSTITUTED 3-(1-OXOISOINDOLIN-2-YL)PIPERIDINE-2,6-DIONE DERIVATIVES AND USES THEREOF | NOVARTIS AG (CH) | 2023-08-31 | — | — | US | disclosed |
| EP-4188549-A1 | HETEROARYL SUBSTITUTED 3-(1-OXOISOINDOLIN-2-YL)PIPERIDINE-2,6-DIONE DERIVATIVES AND USES THEREOF | Novartis AG (CH) | 2023-06-07 | — | — | EP | disclosed |
| WO-2007123953-A2 | PHOSPHODIESTERASE 4 INHIBITORS | MEMORY PHARMACEUTICALS CORPORATION (US) | 2007-11-01 | — | — | WO | disclosed |
| US-20070203197-A1 | Phosphodiesterase 4 inhibitors | HOPPER ALLEN | 2007-08-30 | — | — | US | disclosed |
| EP-1799673-A1 | PYRAZOLE DERIVATIVES AS PHOSPHODIESTERASE 4 INHIBITORS | Memory Pharmaceuticals Corporation (US) | 2007-06-27 | — | — | EP | disclosed |
| US-7226930-B2 | Phosphodiesterase 4 inhibitors | MEMORY PHARMACEUTICAL CORPORATION (US) | 2007-06-05 | — | — | US | disclosed |
| CN-1809559-A | Pyrazole derivatives as phosphodiesterase 4 inhibitors | MEMORY PHARM CORP (US) | 2006-07-26 | — | — | CN | disclosed |
| US-20060154960-A1 | Phosphodiesterase 4 inhibitors | MEMORY PHARMACEUTICALS CORPORATION | 2006-07-13 | — | — | US | disclosed |
| WO-2006044528-A1 | PYRAZOLE DERIVATIVES AS PHOSPHODIESTERASE 4 INHIBITORS | MEMORY PHARMACEUTICALS CORPORATION (US) | 2006-04-27 | — | — | WO | disclosed |
| EP-1631568-A1 | PYRAZOLE DERIVATIVES AS PHOSPHODIESTERASE 4 INHIBITORS | Memory Pharmaceuticals Corporation (US) | 2006-03-08 | — | — | EP | disclosed |
| US-20040229918-A1 | Phosphodiesterase 4 inhibitors | MEMORY PHARMACEUTICALS CORPORATION | 2004-11-18 | — | — | US | disclosed |
| WO-2004094411-A1 | PYRAZOLE DERIVATIVES AS PHOSPHODIESTERASE 4 INHIBITORS | MEMORY PHARMACEUTICALS CORPORATION (US) | 2004-11-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070203197-A1 | Phosphodiesterase 4 inhibitors | PDE4A, PDE4B, PDE12 | CYP19A1 1260/4885P2RX7 890/4885RECQL 1347/4885 |
| US-20230271940-A1 | HETEROARYL SUBSTITUTED 3-(1-OXOISOINDOLIN-2-YL)PIPERIDINE-2,6-DIONE DERIVATIVES AND USES THEREOF | XDH, SLCO1B3, ROR1 | CYP19A1 772/4885P2RX7 135/4885RECQL 519/4885 |
| US-20060154960-A1 | Phosphodiesterase 4 inhibitors | PDE4A, PDE4B, PDE12 | CYP19A1 1260/4885P2RX7 890/4885RECQL 1347/4885 |
| US-12384777-B2 | Compounds comprising N-methyl-2-pyridone, and pharmaceutically acceptable salts | TPMT, IL5, P2RY6 | CYP19A1 1957/4885P2RX7 38/4885RECQL 826/4885 |
| US-20040229918-A1 | Phosphodiesterase 4 inhibitors | PDE4A, PDE4B, PDE12 | CYP19A1 1260/4885P2RX7 890/4885RECQL 1347/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.